Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score

Acta Neurologica Scandinavica

Volumn 117, Issue 1, 2008, Pages 21-25

  Guerrero, A L ^a   Laherran E ^a   Gutierrez F ^a   Martin Polo J ^a   Iglesias, F ^a   Alcazar C ^a   Peralta, J ^a   Rostami, P ^a  

^a HOSPITAL RÍO CARRIÓN   (Spain)

Author keywords

Apolipoprotein E; Multiple sclerosis; Severity

Indexed keywords

APOLIPOPROTEIN E;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; RELAPSE; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DISABILITY EVALUATION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 37249071904     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00908.x     Document Type: Article

References (37)

1. Kantarci OH, Andrade MD, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002 123 : 144 59.
2. Roxburgh RHSR, Seaman SR, Masterman T et al. Multiple Sclerosis Severity Score. Neurology 2005 64 : 1144 51.
3. Fazekas F, Strasser-Fuchs S, Kollegger H et al. Apolipoprotein E4 is associated with rapid progression of multiple sclerosis. Neurology 2001 57 : 853 7.
4. Chapman J, Vinokurov S, Achiron A et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001 56 : 312 6.
5. Fazekas F, Enzinger C, Ropele S, Schmidt H, Schmidt R, Strasser-Fuchs S. The impact of our genes: consequences of the apolipoprotein E polymorphisms in Alzheimer disease and multiple sclerosis. J Neurol Sci 2006 245 : 35 9.
6. Dousset V, Gayou A, Brochet B, Iron A. ApoE polymorphisms in multiple sclerosis. Mult Scler 1999 4 : 357 (abstract).
7. Chapman J, Sylantiev C, Nisipeanu P, Korczyn AD. Preliminary observations on APOE 4 allele and progression on disability in multiple sclerosis. Arch Neurol 1999 56 : 1484 7.
8. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE e4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999 67 : 203 5.
9. Ferri C, Sciacca FL, Veglia F et al. APOE epsilon 2-4 and -491 polymorphisms are not associated with MS. Neurology 1999 53 : 888 9.
10. Hamilton AJ, Graham CA, Kirk CW, Mcdonell GV, Hawkins SA. ApoE gene variants and a disease progression index in multiple sclerosis. Mult Scler 1999 5 (Suppl. 1 S34 (abstract).
11. Fazekas F, Strasser-Fuchs S, Schmidt H et al. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 2000 69 : 25 8.
12. Hogh P, Oturai A, Schreiber K et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000 6 : 226 30.
13. Masterman T, Hillert J, Lannfelt L, Corder EH. The e4 allele for APOE doubles the risk of long-term prognosis in multiple sclerosis. Am J Hum Genet 2000 67 : P1957 (abstract).
14. Weatherby SJM, Mann CLA, Davies MB et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000 6 : 32 6.
15. Weatherby SJM, Mann CLA, Fryer AA et al. No association between the APOE e4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000 68 : 532.
16. Haines JL, Schmidt S, Boylston FR et al. Follow-up analysis of the chromosome 19q13 region in multiple sclerosis with single nucleotide polymorphisms. Neurology 2001 56 (Suppl. 3 A96 (abstract).
17. Masterman T, Zhang Z, Hellgren D et al. APOE genotypes and disease severity in multiple sclerosis. Mult Scler 2002 8 : 98 103.
18. Schmidt S, Barcellos LF, Desombre K et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet 2002 70 : 708 17.
19. Schreiber K, Otura AB, Ryder LP et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002 8 : 25 8.
20. Enzinger C, Ropele S, Strasser-Fuchs S et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E4 allele. Arch Neurol 2003 60 : 65 70.
21. Guerrero AL, Bueno V, Hernández MT, Martín-Serradilla JI, Carrasco E, Cuadrado I. Apolipoprotein E polymorphism as a predictor of progression of multiple sclerosis. Neurologia 2003 18 : 146 8.
22. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K. Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. Mult Scler 2003 9 : 382 6.
23. Savettieri G, Andreoli V, Bonavita S et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003 250 : 1094 8.
24. Kantarci OH, Hebrink DD, Achenbach SJ et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004 62 : 811 4.
25. Santos M, DO Carmo Costa M, Edite Rio M et al. Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004 10 : 153 7.
26. Zakrzewska-pniewska B, Styczynska M, Podlecka A et al. Association of apolipoprotein E and mieloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004 10 : 266 71.
27. Zwemmer JNP, Vanveen T, Van winsen L et al. No major association of APOE genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004 10 : 272 7.
28. Al-shammri S, Fatania H, Al-radwan R, Akanji AO. The relationship of APOE genetic polymorphism with susceptibility to multiple sclerosis and its clinical phenotypes in Kuwaiti Arab subjects. Clin Chim Acta 2005 351 : 203 7.
29. Cocco E, Sotgiu A, Costa G et al. HLA-DR, DQ and APOE genotypes and gender influence in Sardinian primary progressive MS. Neurology 2005 64 : 564 6.
30. Pinholt M, Frederiksen JL, Andersen PS, Christiansen M. ApoE in multiple sclerosis and optic neuritis: the apo E-epsilon4 allele is associated with progression of multiple sclerosis. Mult Scler 2005 11 : 511 5.
31. Ramsaransing GS, Heersema DJ, DE Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur J Neurol. 2005 12 : 514 8.
32. Sedano MJ, Calmarza P, Perez L, Trejo JM. No association of apolipoprotein E epsilo4 genotype with faster progression or less recovery of relapses in a Spanish cohort of multiple sclerosis. Mult Scler 2006 12 : 13 8.
33. Masterman T, Hillert J. The telltale scan: APOE 4 in multiple sclerosis. Lancet Neurol 2004 3 : 331.
34. Burwick RM, Ramsay PP, Haines JL et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity. Neurology 2006 66 : 1373 83.
35. Enzinger C, Ropele S, Smith S et al. Accelerated evolution of brain atrophy and black holes in MS patients with APOE-e4. Ann Neurol 2004 55 : 563 9.
36. Destefano N, Bartolozzi ML, Nacmias B et al. Influence of apolipoprotein E4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004 61 : 536 40.
37. Zwemmer J, Uitdehaag B, Van kamp G, Barkhoff F, Polman C. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004 63 : 1139.